Ali Sheikh Muhammad Ebad, Sahito Badaruddin, Khan Hina, Abro Awais, Kumar Sunel, Ali Muhammad Usman
Department of Trauma & Orthopedics, Chelsea & Westminster Hospital, London, United Kingdom.
Department of Trauma & Orthopedics, Dow University of Health Sciences (DUHS), Sindh, Pakistan.
Rev Bras Ortop (Sao Paulo). 2025 Jul 10;60(2):1-9. doi: 10.1055/s-0045-1809397. eCollection 2025 Apr.
To retrospectively compare the impact of using neoadjuvant denosumab for Campanacci grade-III giant cell tumor (GCT) of the proximal femur involving the hip joint.
We retrospectively reviewed 18 cases of Campanacci grade-III GCT of the proximal femur receiving surgery between January 2014 and December 2019 from our hospital. One group of 10 patients received weekly neoadjuvant denosumab 120 mg for 4 weeks, while the other group of 8 patients did not receive denosumab before surgery. Two patients were subjected to intralesional curettage while the others received resection and hip arthroplasty. Comparisons were made using unpaired -test and Fisher's exact test. Functional outcomes were assessed by revised Musculoskeletal Tumor Society (MSTS) score and Harris Hip Score (HHS) at 6 weeks, 6 months, and 12 months of follow-up, as well as incidence of recurrence.
The comparison of the mean MSTS scores of the denosumab and non-denosumab groups was as follows: 24.0 ± 6.5 versus 20.0 ± 6.0 ( = 0.04) at 6 weeks respectively; 26.0 ± 5.0 versus 23.0 ± 0.67 ( = 0.04) at 6 months respectively; and 28.8 ± 1.7 versus 29.5 ± 0.33 ( = 0.35) at 12 months respectively. The comparison of HHSs between the denosumab and non-denosumab groups was as follows: 61.02 ± 7.36 versus 48.52 ± 3.97 ( = 0.03) at 6 weeks respectively; 81.1 ± 2.97 versus 79.15 ± 3.24 ( = 0.82) at 6 months respectively; and 89.84 ± 3.75 versus 90.05 ± 3.00 ( = 0.38) at 12 months respectively. There was no recurrence.
Denosumab was clinically effective in improving the short-term functional outcomes, but long-term functional outcomes remained similar between the groups. We did not find an increased recurrence rate in the denosumab group.
回顾性比较使用新辅助地诺单抗治疗累及髋关节的股骨近端坎帕纳奇Ⅲ级骨巨细胞瘤（GCT）的影响。
我们回顾性分析了2014年1月至2019年12月在我院接受手术的18例股骨近端坎帕纳奇Ⅲ级GCT患者。一组10例患者每周接受120mg新辅助地诺单抗治疗，共4周，另一组8例患者在手术前未接受地诺单抗治疗。2例患者接受病灶内刮除术，其余患者接受切除术和髋关节置换术。采用非配对t检验和Fisher精确检验进行比较。在随访的6周、6个月和12个月时，通过修订的肌肉骨骼肿瘤学会（MSTS）评分和Harris髋关节评分（HHS）评估功能结果以及复发率。
地诺单抗组和非地诺单抗组平均MSTS评分比较如下：6周时分别为24.0±6.5和20.0±6.0（P = 0.04）；6个月时分别为26.0±5.0和23.0±0.67（P = 0.04）；12个月时分别为28.8±1.7和29.5±0.33（P = 0.35）。地诺单抗组和非地诺单抗组HHS比较如下：6周时分别为61.02±7.36和48.52±3.97（P = 0.03）；6个月时分别为81.1±2.97和79.15±3.24（P = 0.82）；12个月时分别为89.84±3.75和90.05±3.00（P = 0.38）。无复发情况。
地诺单抗在改善短期功能结果方面临床有效，但两组间长期功能结果相似。我们未发现地诺单抗组复发率增加。
